Thailand vs Japan IVF Success Rates: An Objective Analysis Based on Clinical Data
Opening: Clinical Decision-Making Logic
Clinical Consultation Scenario — In a reproductive medicine clinic, a 42-year-old patient with an AMH of 0.8 ng/mL holds success rate reports from both a Thai and a Japanese institution. A Thai center reports "approximately 52% clinical pregnancy rate for women under 45," while a Japanese institution shows "approximately 14% live birth rate for ages 40-42." The stark difference in data makes it difficult for the patient to decide and can easily foster unrealistic expectations. In reality, there are fundamental differences in the statistical definitions, patient selection criteria, and legal policy environments between the two countries' success rate data, and directly comparing the numbers can be misleading.
Module A: Direct AnswerCore Differences in Success Rates Between the Two Countries
There are differences in IVF success rate data between Thailand and Japan, but the nature and extent of these differences need to be examined across specific dimensions. For patients under 35, the gap in single-transfer success rates between the two countries is relatively small. However, for those over 40, the data reported by Thailand is generally higher than that of Japan. Yet, this gap primarily reflects differences in medical strategies, patient selection mechanisms, and legal policy environments, rather than a simple difference in technological proficiency.
Underlying Logic Behind the Differences
The sources of the differences in success rate data between the two countries are mainly threefold:
- Different Patient Population Structures: The proportion of patients over 40 undergoing IVF in Japan has been increasing year by year. In 2022, the JSOG report indicated that cycles for women over 40 accounted for over 42% of all cycles. In Thailand's major reproductive centers, the patient population has a higher proportion of those under 35 and aged 36-39, and some centers have strict entry screening for older patients.
- Differences in Ovarian Stimulation and Embryo Culture Strategies: Japan widely adopts mild stimulation and natural cycle protocols, resulting in fewer oocytes per retrieval but potentially better endometrial receptivity, with cumulative live birth rates that are not inferior. Thailand primarily uses conventional stimulation protocols, yielding more oocytes per retrieval, and combined with PGT selection, achieves higher per-transfer success rates.
- Legal and Ethical Policy Constraints: Japan does not permit PGT (except for a few genetic diseases) and strictly restricts egg and sperm donation. Thailand allows PGT and legally permits egg and sperm donation, providing greater operational flexibility in embryo selection and third-party reproduction, directly boosting per-transfer success data.
Interpretation from a Clinician's Perspective
When interpreting data from both countries, reproductive medicine specialists typically do not look solely at the "per-transfer success rate." The following three dimensions are more critical:
- Cumulative Live Birth Rate: Japan employs mild stimulation strategies. Although the per-transfer success rate is relatively low, through multiple accumulations, the cumulative live birth rate for patients under 35 can reach over 60%, similar to the data for the same age group in Thailand.
- Patient Age and Ovarian Reserve: For patients over 40, Thailand can significantly improve the per-transfer success rate through PGT selection. However, it is important to note that PGT itself results in the loss of some embryos, and the proportion of chromosomally normal embryos is low in older patients, so the actual benefit requires individualized assessment.
- Treatment Risk and Comfort: The risk of OHSS (Ovarian Hyperstimulation Syndrome) with Japan's mild stimulation protocols is extremely low, and cycle cancellations are rarely needed. Thailand's conventional stimulation protocols carry a relatively higher risk of OHSS, but this has been significantly reduced through the use of antagonist protocols and freeze-all embryo strategies.
Differences Between Countries: Japan vs Thailand
The following compares assisted reproduction in the two countries across seven key dimensions to help understand the true picture behind the success rate data:
| Dimension | Japan | Thailand |
|---|---|---|
| Main Ovarian Stimulation Strategy | Primarily mild stimulation, natural cycles, and minimal stimulation | Primarily conventional stimulation, antagonist protocols, and PPOS protocols |
| Per-Transfer Success Rate (Under 35, Live Birth Rate) |
Approximately 28%–33% (JSOG national registry data) | Approximately 40%–48% (self-reported by top centers, including PGT selection) |
| Per-Transfer Success Rate (Over 40, Live Birth Rate) |
Approximately 10%–15% (ages 40-42) | Approximately 18%–25% (ages 40-42, after PGT selection) |
| PGT Policy | Generally not permitted (except for specific severe genetic diseases) | Permitted and widely used for advanced maternal age, recurrent failure, and genetic disease screening |
| Egg / Sperm Donation | Strictly restricted, almost unavailable for commercial use | Legally permitted, with established egg and sperm banks |
| Patient Population Characteristics | Balanced across age groups, high proportion of older patients, primarily local patients | Primarily cross-border patients, high proportion aged 35-42, some centers have age准入 restrictions |
| Approximate Cost per Cycle | Approximately 2.5–4 million JPY (USD 17,000–27,000) | Approximately 500,000–900,000 THB (USD 14,000–25,000, including PGT) |
*Data based on industry public reports and clinical consensus. Specific values vary by center, protocol, and individual patient circumstances.
Module G: Easily Overlooked DetailsDetails Often Overlooked
When comparing success rates between the two countries, the following details are frequently ignored but have a significant impact on data interpretation:
- Age Statistical Definition: Japan's JSOG data is calculated based on "age at treatment start," while some Thai centers calculate based on "age at transfer." The latter can lead to higher reported data for the older age group.
- Inclusion of PGT Cycles: The high success rate data from Thailand mostly comes from PGT cycles. PGT eliminates a large number of chromosomally abnormal embryos, and only screened "good embryos" are transferred, naturally resulting in a higher per-transfer success rate. Japan does not use PGT, so transferred embryos include a certain proportion of abnormal ones, lowering the success rate.
- Frozen vs Fresh Embryo Transfer: Thailand primarily uses frozen embryo transfers (freeze-all strategy), while Japan has a more balanced ratio of fresh to frozen transfers. Frozen embryo transfers have a slightly higher success rate in specific patient populations compared to fresh transfers.
- Completeness of Data Sources: Japan's JSOG registry covers approximately 99% of reproductive centers nationwide, with complete and audited data. Thailand lacks a national registry system, and data self-reported by individual centers may involve selective disclosure.
Common Misconceptions
Reality: The cumulative live birth rates for patients under 35 are similar in both countries. Thailand's higher per-transfer success rate comes at the cost of more aggressive embryo selection and a higher cycle cancellation rate (due to no embryos available after PGT).
Reality: Japan's adoption of mild stimulation strategies is based on considerations for patient safety and financial burden, not a lack of technical capability. Japan is at the forefront of the world in basic technologies such as oocyte cryopreservation, vitrification, and intracytoplasmic sperm injection (ICSI).
Reality: Success rates are population-based statistical results. Individual success is influenced by multiple factors including age, AMH, FSH, antral follicle count, obstetric history, and chromosomal status. A center's published data cannot be directly used to predict an individual's outcome.
Typical Scenario Analysis
Scenario 1: 34 years old, AMH 2.5 ng/mL, tubal factor infertility, no genetic history
Such patients can achieve high success rates in both countries. With Japan's mild stimulation or natural cycles, the cumulative live birth rate is approximately 55-65%. With Thailand's conventional stimulation plus PGT, the per-transfer success rate is about 45-50%, and the cumulative live birth rate is about 60-70%. The difference between the two countries is small, and the choice depends more on preference for treatment philosophy, budget, and schedule.
Scenario 2: 41 years old, AMH 0.9 ng/mL, 2 previous failed transfers, desires PGT
Thailand is a more suitable choice because Japan does not allow PGT and cannot perform chromosomal screening on embryos. Thailand can use PGT-A to screen for chromosomally normal embryos, improving the per-transfer success rate. Note: In PGT cycles for older patients, approximately 50-60% may have no euploid embryos available, so psychological preparation is necessary.
Scenario 3: 38 years old, AMH 1.8 ng/mL, Polycystic Ovary Syndrome (PCOS), high risk of severe OHSS
Japan's mild stimulation protocol can significantly reduce the risk of OHSS while ensuring a considerable cumulative live birth rate. Although Thailand can also use mild stimulation protocols, the mainstream strategy still favors conventional stimulation, with a relatively higher risk of OHSS. For individuals at high risk of OHSS, Japan may be a safer choice.
Module Q: Frequently Asked QuestionsAnswers to High-Frequency Questions
It cannot be simply answered which is higher. For patients under 35, the cumulative live birth rates are similar. For patients over 40, Thailand reports higher per-transfer success rates due to the allowance of PGT and stricter patient selection. It is recommended to make a comprehensive judgment based on age, ovarian reserve, need for PGT, budget, and preference for treatment philosophy.
For patients over 42, Thailand's legal advantages in PGT screening and egg donation are more prominent. Japan's live birth rates for older patients are indeed lower due to the prohibition of PGT and egg donation. If the patient declines egg donation and wishes to use their own eggs, Thailand can improve per-transfer efficiency through PGT screening. Japan is more suitable for a strategy of accumulating embryos through mild stimulation.
Low AMH (e.g., below 0.5 ng/mL) indicates diminished ovarian reserve but does not mean there is no chance of pregnancy. Japan's mild stimulation protocol is widely used in the low AMH population, accumulating embryos through consecutive retrievals, with good cumulative live birth rates. Thailand also has mild stimulation protocols for low AMH, but the overall strategy still leans towards conventional stimulation. Patients with low AMH are advised to prioritize mild stimulation or natural cycle protocols, where Japan has more extensive clinical experience.
It is generally recommended to start preparation 3-6 months in advance. Required materials and steps include: ① Basic fertility assessment (AMH, FSH, LH, antral follicle count, semen analysis); ② Chromosomal testing and genetic counseling; ③ Infectious disease screening (HIV, Hepatitis B, Hepatitis C, Syphilis, etc.); ④ Uterine cavity evaluation (e.g., hysteroscopy or saline infusion sonography); ⑤ Passport and visa processing (Thailand medical visa or visa on arrival, Japan medical stay visa); ⑥ Medical record establishment and translation/notarization. Some test results have limited validity (e.g., infectious disease screening is usually valid for 6 months), so schedule accordingly.
Both countries have reached internationally advanced levels in basic laboratory technologies (vitrification, ICSI, embryo culture). The differences are mainly: ① Japan places greater emphasis on the stability of the culture environment, using low-oxygen culture and individualized culture media; Thailand focuses more on embryo screening efficiency, widely using time-lapse imaging and PGT. ② Japan has accumulated a large amount of data in oocyte cryopreservation, especially for fertility preservation in cancer patients; Thailand has more experience in PGT technology and possesses a wider range of genetic analysis platforms.
Practitioner's Observation
Having worked in the assisted reproduction industry for many years, a common phenomenon is that patients are easily led by a single success rate number, ignoring the more important individualized factors behind it. The difference between Thailand and Japan is essentially a difference in two medical philosophies and policies — Japan leans towards "safety, accessibility, accumulation," while Thailand leans towards "efficiency, selection, precision." There is no absolute good or bad, only what is suitable or not.
For patients seeking cross-border medical treatment, it is advisable to assess, alongside the success rate, your own tolerance for risk, time, and financial costs, as well as your most important treatment goal (whether it is rapid success in a single attempt or accumulating opportunities with minimal risk). These factors often determine the final treatment experience and outcome more than the numbers themselves.
Closing: Risk ReminderReferences and Data Sources: Annual registry reports of the Japan Society of Obstetrics and Gynecology (JSOG); Public materials from the Thai Society for Reproductive Medicine (TSRM); Industry consensus and clinical practice guidelines. This content is for informational purposes only and does not constitute medical advice.
